TY - JOUR T1 - New Approaches in Targeted Therapy for Medulloblastoma in Children JF - Anticancer Research JO - Anticancer Res SP - 1715 LP - 1726 DO - 10.21873/anticanres.14936 VL - 41 IS - 4 AU - HENRIETTA MAIER AU - TINA DALIANIS AU - OURANIA N. KOSTOPOULOU Y1 - 2021/04/01 UR - http://ar.iiarjournals.org/content/41/4/1715.abstract N2 - Medulloblastoma (MB) is the most frequent malignant brain tumor in children. Treatment of MB is based on histopathological and molecular stratification, and includes surgical intervention, often with craniospinal irradiation and adjuvant chemotherapy. Unfortunately, however, this treatment leads to a high morbidity rate, and it does not cure all patients either, with around 30% succumbing to their disease. With improved cancer genomics and better molecular characterization, MB has been classified into four major subgroups, wingless-activated, sonic hedgehog-activated, Group 3, and Group 4, with each group consisting of additional subtypes. Recently disclosed genetic drivers of MB may in the future help improve treatment, and in this way reduce therapy-related toxicity. In this review, we describe the heterogeneity of the MB subgroups, and potential new options for targeted therapy. ER -